Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

Phase 2 Not yet recruiting 50 enrolled Zhiguo Luo, MD, PhD

NaSingle-groupOpen-labelTreatment

Summary

This study is a single-arm, open-label, multicenter Phase II clinical trial designed to observe and evaluate the efficacy and safety of Pucotenlimab in combination with MRG002 in patients with HER2-positive (IHC 2+ or 3+) cancer of unknown primary.

Timeline

Start: 2025-03-08
Primary completion: 2027-03-08
Completion: 2028-08-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pucotenlimab	Monoclonal antibody	200 mg	Intravenous
Subject	TRASTUZUMAB VEDOTIN	Unknown	2.2 mg/kg	—

Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

Summary

Timeline

Drugs

Indications